Incyte announced positive topline results from the TRuE-AD clinical trial program (TRuE-AD1 and TRuE-AD2) of ruxolitinib cream for the treatment of atopic dermatitis in patients aged 12 years and older.
Positive topline data were announced from the pivotal phase 3 TRuE-AD2 study of ruxolitinib cream for the treatment of atopic dermatitis in patients aged ≥12 years.
Dupixent, an interleukin-4 receptor alpha antagonist, is currently approved for moderate to severe atopic dermatitis in patients ≥12 years old who are not adequately controlled with topical prescription therapies or when they are not advisable.
Results showed that the 4mg dose of baricitinib plus TCS met the primary end point, with 31.5% of patients achieving EASI75 compared with 17.2% of patients in the placebo plus TCS group (P ≤.05).
Sol-Gel Technologies announced positive topline results from two pivotal phase 3 clinical trials for Twyneo (microencapsulated benzoyl peroxide, 3% and microencapsulated tretinoin, 0.1%) for the treatment of acne vulgaris.
The FDA has approved Arazlo (tazarotene; Ortho Dermatologics) Lotion 0.045% for the treatment of acne vulgaris in patients aged 9 years and older.
LEO Pharma announced positive topline results from three pivotal phase 3 studies of tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis.
The FDA has granted Fast Track designation to lebrikizumab for the treatment of moderate-to-severe atopic dermatitis.
Nemolizumab is a first-in-class humanized monoclonal antibody that blocks the signaling of IL-31 by targeting IL-31 receptor alpha.
Minocycline foam 4% (Amzeeq; Foamix) appears to be safe and effective for moderate-to- severe acne, according to findings from a long-term, open-label safety study.
